These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 23395225)

  • 1. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
    Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
    Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
    Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
    Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The advent of biosimilar therapies in rheumatology--"O brave new world".
    Scheinberg MA; Kay J
    Nat Rev Rheumatol; 2012 Jun; 8(7):430-6. PubMed ID: 22664834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
    Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
    Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Position paper of Italian rheumatologists on the use of biosimilar drugs.
    Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
    Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of biosimilar candidate drugs in rheumatology: a literature review.
    Araújo F; Cordeiro I; Teixeira F; Gonçalves J; Fonseca JE
    Acta Reumatol Port; 2014; 39(1):19-26. PubMed ID: 24811458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy: Facing up to biosimilar agents--the ACR position.
    Scheinberg M
    Nat Rev Rheumatol; 2015 Jun; 11(6):322-4. PubMed ID: 25907701
    [No Abstract]   [Full Text] [Related]  

  • 10. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in pediatric rheumatology and their introduction into routine care.
    Aragon Cuevas O; Hedrich CM
    Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar medicines for psoriasis. Positioning of the Mexican Academy of Dermatology.
    García-Hidalgo L; Méndez-Flores S; Carrillo-Vázquez S; Estrada-Aguilar L; García-Salazar MDR; Gómez-Flores M; López-Tello A; Charli-Joseph Y; Maldonado-García C; Serrano-Jaén L
    Gac Med Mex; 2020; 156(Supl):1-14. PubMed ID: 32484168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
    Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
    [No Abstract]   [Full Text] [Related]  

  • 17. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
    El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
    Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in rheumatology: current perspectives and lessons learnt.
    Dörner T; Kay J
    Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in rheumatology: perspective and concerns.
    Scheinberg MA; Azevedo VF
    Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.